TECENTRIQ + CARBOPLATIN/ETOPOSIDE

A proven connection in 1L SCLC

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer
(ES-SCLC).1

Setting the standard of care in SCLC

TECENTRIQ was the first treatment advance in SCLC in over 20 years, showing a significant survival benefit in a hard-to-treat patient population.2

IMpower133: A Phase 3 efficacy trial in first-line ES-SCLC2 

 

A Phase 3 study in patients (n=403) with extensive-stage SCLC randomised to receive induction therapy with carboplatin and etoposide in combination with TECENTRIQ or placebo, and then TECENTRIQ or placebo maintenance therapy until disease progression or unacceptable toxicity. Primary endpoints included OS and PFS.2

  • dddd

    Significant OS benefit with 30% reduction in risk of death versus carboplatin/etoposide alone2

    A statistically significant benefit in median OS in the population treated with TECENTRIQ + carboplatin/etoposide versus carboplatin/etoposide alone (12.3 months vs 10.3 months; HR=0.70; 95% CI: 0.54, 0.91)1,2

    Carbo/etop; carboplatin/etoposide.

  • dddd

    Significant improvement in PFS versus carboplatin/etoposide alone2

    A statistically significant improvement in PFS was also observed with TECENTRIQ + carboplatin/etoposide versus the control arm (5.2 months vs 4.3 months; HR=0.77; 95% CI: 0.62, 0.96).2

    Carbo/etop, carboplatin/etoposide.

  • dddd

    More than 50% of patients treated upfront with TECENTRIQ combination alive at 1 year2

    52% of patients treated up front with TECENTRIQ + carboplatin and etoposide were alive at 1 year vs 38% receiving carboplatin and etoposide.2

    Carbo/etop; carboplatin/etoposide.

  • dddd

    More than 30% of patients treated with TECENTRIQ combination alive at 1.5 years4†

    34% of patients treated with TECENTRIQ + carboplatin and etoposide were alive at 1.5 years vs 21% receiving carboplatin and etoposide.4

    Carbo/etop; carboplatin/etoposide.
    †As of data cut-off date 24th January 2019, median follow-up: 22.9 months.

TECENTRIQ: First major treatment advance for first-line ES-SCLC in over 20 years4,5

See how TECENTRIQ can help patients with lung cancer

: Icon of a lung representing small-cell lung cancer
Icon of a lung representing lung cancer.
  • References & Notes

    References & Notes

    1. TECENTRIQ (atezolizumab), Summary of Product Characteristics. June 2022. Available from: https://www.ema.europa.eu/ (Accessed June 2022).
     

    2. Horn L, Mansfield AS, Szczęsna A, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.
    N Engl J Med. 2018;379:2220-2229.

     

    3. Liu et al. IMpower133 LTS, ESMO2020.

     

    4. Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549-561.

     

    5. Armstrong SA, Liu SV. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. Adv Ther. 2019;36:1826-1832.